Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia

Autor: K Wallman, G Tjønnfjord, C M Stolt, M Hedenus, D Heldal, E Hippe, F Albertioni, Stein A. Evensen, Gunnar Juliusson, Claes Malm

Publikováno v: Journal of Clinical Oncology. 13:989-995

PURPOSE To evaluate the clinical efficacy and safety of 2-chlorodeoxyadenosine (CdA) when administered by subcutaneous injection to patients with symptomatic hairy cell leukemia (HCL), and to evaluate predictive factors for response. PATIENTS AND MET

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99c3f0adf146f6c05c76425c65f961e0
https://doi.org/10.1200/jco.1995.13.4.989

Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies

Autor: Anders Österborg, M. Hedenus, Yvonne Brandberg, G. Iosava, D. Messinger, K. Abdulkadyrov, V. Molostova

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 20(10)

PURPOSE: To investigate the effect of recombinant human erythropoietin (epoetin beta) on anemia, transfusion need, and quality of life (QOL) in severely anemic patients with low-grade non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd5a2331b5394c69dd35fe0aea77535f
https://pubmed.ncbi.nlm.nih.gov/12011126

Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group

Autor: H, Brincker, J, Westin, N, Abildgaard, P, Gimsing, I, Turesson, M, Hedenus, J, Ford, A, Kandra

Publikováno v: British journal of haematology. 101(2)

In order to study whether oral bisphosphonate therapy might prevent or reduce skeletal-related morbidity in patients with newly diagnosed multiple myeloma who required chemotherapy, 300 patients were included in a randomized multi-centre trial. Patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::dfa0f0a0163a5698ab38962c006c270d
https://pubmed.ncbi.nlm.nih.gov/9609523

Refractory myelomatosis treated with mitoxantrone in combination with vincristine and prednisone (NOP-regimen): a phase II study. The Nordic Myeloma Study Group (NMSG)

Autor: P, Gimsing, O W, Bjerrum, E, Brandt, J, Ellegaard, S A, Evensen, M M, Hansen, M, Hedenus, E, Hippe, N, Keldsen, I, Palva

Publikováno v: British journal of haematology. 77(1)

In a phase II study, patients with refractory myelomatosis were treated with a combination chemotherapy (NOP regimen): mitoxantrone (bolus injection of 4 mg/m2 on days 1-4), vincristine (continuous infusion of 0.4 mg/24 h on days 1-4) and prednisone

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d68ef58f85d6dcd9ce9682cc1f373f9b
https://pubmed.ncbi.nlm.nih.gov/1772791

The role of nuclear energy in low carbon energy transition: evidence from panel data approach in EU.

Autor: Wojciechowski W; Warsaw School of Economics, Al. Niepodległości 162, 02-554, Warsaw, Poland., Streimikiene D; Bioeconomy Research Institute, Vytautas Magnus university, Akademija, Kaunas Region, Studentu 11, LT-53361, Lithuania. dalia@mail.lei.lt., Wojciechowski A; Institute of Information Technology, Lodz University of Technology, Wólczanska 215, 90-924, Lodz, Poland., Bilan Y; Bioeconomy Research Institute, Vytautas Magnus university, Akademija, Kaunas Region, Studentu 11, LT-53361, Lithuania.

Publikováno v: Environmental science and pollution research international [Environ Sci Pollut Res Int] 2023 Dec; Vol. 30 (59), pp. 124353-124373. Date of Electronic Publication: 2023 Nov 24.